Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort.

被引：1
|
作者：
Liebermann, N.
Baehner, F. L.
Soussan-Gutman, L.
Klang, S.
Yoshizawa, C.
Shak, S.
Siegelmann-Danieli, N.
机构：
[1] Clalit Hlth Serv, Tel Aviv, Israel
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Teva Pharmaceut Ind, Netanya, Israel
[4] Genom Hlth, Redwood City, CA USA
[5] Maccabi Hlth Org, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
632
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Evaluation of recurrence score and traditional clinicopathologic metrics in a large ER-positive, lymph node-negative patient cohort
    Baehner, F. L.
    Liebermann, N.
    Shak, S.
    Klang, S.
    Yoshizawa, C.
    Lior, S.
    Siegelmann-Danieli, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [2] Evaluation of Recurrence Score, Nodal Status and Traditional Clinicopathologic Metrics in a Large ER Positive Patient Cohort
    Liebermann, N.
    Klang, S. H.
    Soussan-Gutman, L.
    Shak, S.
    Yoshizawa, C.
    Baehner, F. L.
    Siegelmann-Danieli, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S175 - S175
  • [3] Clinicopathologic Factors Predictive of Recurrence in Lymph Node-negative Gastric Adenocarcinoma
    Hanna, Andrew
    Kennedy, Gregory T.
    Azari, Feredun
    Kim-Kiselak, Caroline
    Goodsell, Kristin
    Burkbauer, Laura
    DeMatteo, Ronald
    Fraker, Douglas L.
    Dempsey, Daniel
    Roses, Robert
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 401 - 402
  • [4] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score
    Tang, G.
    Costantino, J. P.
    Crager, M.
    Shak, S.
    Wolmark, N.
    CANCER RESEARCH, 2010, 70
  • [6] Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
    Poorvu, Philip D.
    Gelber, Shari, I
    Rosenberg, Shoshana M.
    Ruddy, Kathryn J.
    Tamimi, Rulla M.
    Collins, Laura C.
    Peppercorn, Jeffrey
    Schapira, Lidia
    Borges, Virginia F.
    Come, Steven E.
    Warner, Ellen
    Jakubowski, Debbie M.
    Russell, Christy
    Winer, Eric P.
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 725 - +
  • [7] Utilization of oncotype DX in node-negative, ER-positive breast cancer patients
    Patel, H.
    Hook, K.
    Kaplan, C.
    Davidson, R.
    DeMichele, A.
    Fox, K. R.
    Domchek, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach
    Tang, G.
    Cuzick, J.
    Wale, C.
    Costantino, J. P.
    Crager, M.
    Shak, S.
    Wolmark, N.
    Dowsett, M.
    Forbes, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Gulisa Turashvili
    Joanne F. Chou
    Edi Brogi
    Monica Morrow
    Maura Dickler
    Larry Norton
    Clifford Hudis
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2017, 166 : 69 - 76
  • [10] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Turashvili, Gulisa
    Chou, Joanne F.
    Brogi, Edi
    Morrow, Monica
    Dickler, Maura
    Norton, Larry
    Hudis, Clifford
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 69 - 76
12345